¶ 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap
.png)
2019 novel Coronavirus Global research and innovation forum: towards a research roadmap was a private conference hosted by the World Health Organization's R&D Blueprint and the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R). The event took place in Geneva, Switzerland on February 11-12, 2020.[1]
¶ Participants and agenda
Session 1: Setting the Scene
| Name | Affiliation | Topic(s) |
|---|---|---|
| Tedros Adhanom Ghebreyesus | World Health Organization | Opening Remarks |
| Yazdan Yazdanpanah | Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) | Objectives of the meeting |
| Michael Ryan | World Health Organization | Overview of the outbreak situation and control measures being implemented |
| Representative from China | - | Epidemiological situation and current research efforts in China |
| R&D Blueprint co-leads | R&D Blueprint | Overview of WHO R&D Blueprint efforts |
| Isabella Eckerle | Centre for Emerging Viral Diseases | Virus: natural history, transmission and diagnostics |
| Christian Drosten | German Centre for Infection Research (DZIF) | Virus: natural history, transmission and diagnostics |
| Sophie von Dobschuetz | Food and Agriculture Organization (FAO) | Animal and environmental research on the virus origin, and management measures at the human-animal interface |
| Peter Daszak | EcoHealth Alliance | Animal and environmental research on the virus origin, and management measures at the human-animal interface |
| Farida Al Hosani | Abu Dhabi Public Health Center | Animal and environmental research on the virus origin, and management measures at the human-animal interface |
| Gabriel Leung | Li Ka Shing Faculty of Medicine | Epidemiological studies |
| Yae-Jean Kim | Sungkyunkwan University | Clinical characterization and management |
| Robert Fowler | Sunnybrook Research Institute, Dalla Lana School of Public Health | Clinical characterization and management |
| Anna Levin | Hospital das Clínicas, Brazilian Health Regulatory Agency, São Paulo State Health Department | Infection prevention and control, including health care workers’ protection |
| John Conly | AHS COVID-19 Scientific Advisory Group, UNITY Studies | Infection prevention and control, including health care workers’ protection |
| Marco Cavaleri | European Medicines Agency (EMA) | Candidate therapeutics R&D |
| Ana Laura Salvati | Italian Medicines Agency (AIFA) | Candidate therapeutics R&D |
| Anuradha Poonepalli | Health Sciences Authority (HSA) | Candidate vaccines R&D |
| Philip Krause | Food and Drug Administration (FDA) | Candidate vaccines R&D |
| Beatriz da Costa Thome | Federal University of São Paulo | Ethical considerations for research |
| Ross Upshur | Dalla Lana School of Public Health, Ontario COVID-19 Bioethics Table | Ethical considerations for research |
| Nina Gobat | R&D Blueprint, Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE), European Clinical Research Alliance for Infectious Diseases (ECRAID) | Integrating social sciences in the outbreak response |
| Emily Chan | Government of Hong Kong, Chinese University of Hong Kong | Integrating social sciences in the outbreak response |
Session 2: Defining Knowledge Gaps, Research Priorities and a Governance Framework
| Name | Affiliation | Topic(s) |
|---|---|---|
| Sophie van de Werf | Pasteur Institute | Virus: natural history and transmission and diagnostics |
| Isabella Eckerle | Centre for Emerging Viral Diseases | Virus: natural history and transmission and diagnostics |
| Sophie von Dobschuetz | - | Animal and environmental research on the virus origin, and management measures at the human-animal interface |
| William Karesh | EcoHealth Alliance | Animal and environmental research on the virus origin, and management measures at the human-animal interface |
| Farida Al Hosani | Abu Dhabi Public Health Center | Epidemiological studies |
| Gabriel Leung | Li Ka Shing Faculty of Medicine | Epidemiological studies |
| Yae-Jean Kim | Sungkyunkwan University | Clinical characterization and management |
| John Marshall | Unity Health Toronto | Clinical characterization and management |
| Srinivas Moorthy | - | Clinical characterization and management |
| Anna Levin | Hospital das Clínicas, Brazilian Health Regulatory Agency, São Paulo State Health Department | Infection prevention and control, including health care workers’ protection |
| Andreas Voss | International Society of Antimicrobial Chemotherapy (ISAC) | Infection prevention and control, including health care workers’ protection |
| Ana Laura Salvati | Italian Medicines Agency (AIFA) | Candidate therapeutics R&D |
| Marco Cavaleri | European Medicines Agency (EMA) | Candidate therapeutics R&D |
| Anuradha Poonepalli | Health Sciences Authority (HSA) | Candidate vaccines R&D |
| Philip Krause | Food and Drug Administration (FDA) | Candidate vaccines R&D |
| Beatriz da Costa Thome | Federal University of São Paulo | Ethical considerations for research |
| Ross Upshur | Dalla Lana School of Public Health, Ontario COVID-19 Bioethics Table | Ethical considerations for research |
| Lina Moses | Tulane School of Public Health and Tropical Medicine | Social sciences in the outbreak response |
| Emily Chan | Government of Hong Kong, Chinese University of Hong Kong | Social sciences in the outbreak response |
| Jane Ellison | World Health Organization | Funders coordination and perspectives |
| Yazdan Yazdanpanah | Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) | Funders coordination and perspectives |
Session 3: Defining Key Priorities and Overall Objectives of the Global Research Roadmap
| Name | Affiliation | Topic(s) |
|---|---|---|
| Nísia Trindade Lima | Brazil Ministry of Health, Lancet COVID-19 Commission | Plenary debate on the implications of the outcomes of the thematic areas |
| Chikwe Ihekweazu | World Health Organization | Plenary debate on the implications of the outcomes of the thematic areas |
Session 4: Optimizing Funding Efforts
| Name | Affiliation | Topic(s) |
|---|---|---|
| Yazdan Yazdanpanah | Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) | Funders discussion panel |
| Jane Ellison | World Health Organization | Funders discussion panel |
Session 5: Conclusions and Next Steps
| Name | Affiliation | Topic(s) |
|---|---|---|
| Jeremy Farrar | Wellcome Trust | Taking stock of deliberations and report back to Dr Tedros |
| Marie-Paule Kieny | Drugs for Neglected Diseases Initiative (DNDi) | Taking stock of deliberations and report back to Dr Tedros |
| Nísia Trindade Lima | Brazil Ministry of Health, Lancet COVID-19 Commission | Taking stock of deliberations and report back to Dr Tedros |
| Chikwe Ihekweazu | World Health Organization | Taking stock of deliberations and report back to Dr Tedros |
| Soumya Swaminathan | World Health Organization | Next steps: Summary by the WHO Secretariat |
¶ External links
2019 novel Coronavirus Global research and innovation forum: towards a research roadmap AGENDA. (2020). GLOPID-R. https://web.archive.org/web/20230208185417/https://www.glopid-r.org/wp-content/uploads/2020/02/covid-19-global-research-and-innovation-forum-2020-program.pdf ↩︎